EDMONTON, Sept. 27 /CNW/ - Isotechnika today announced that two principal
investigators involved in the Company's Phase 3 psoriasis trials have been
selected to give oral presentations during the 21st World Dermatology
Conference in Buenos Aires, Argentina.
Dr. Wayne Gulliver and Dr. Wolfram Sterry will make separate
presentations during the Psoriasis and Related Disorders interactive session
on October 1, 2007. The presentations titled "The Essence Study: A Positive
and Placebo Controlled, Double-Blind, Multicentre Study of ISA247 in Moderate
to Severe Plaque Psoriasis" and "ISA247: Well Tolerated After 60 Weeks of
Continuous Therapy" will be available to all interested parties by visiting
the "Presentations" section under "For Investors" of the Company's corporate
web site at www.isotechnika.com.
Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments while offering therapeutic choices to clinicians.
Isotechnika looks to become the market leader of drug therapies for
indications such as transplantation of solid organs (with Hoffman La Roche)
and treatment of autoimmune disorders such as uveitis (with Lux Biosciences)
Calcineurin inhibitors are used in the vast majority of all transplant
patients from the time of transplant, continuing for the entire life of the
patient. The market for these drugs currently exceeds $2 billion annually. Use
of the only other two marketed calcineurin inhibitors, cyclosporin and
tacrolimus, while both efficacious, is associated with various significant
Isotechnika's lead drug, ISA247, has successfully completed a Phase 3
Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is
currently being investigated in a Phase 3 European/Canadian psoriasis trial
and a Phase 2b North American trial for the prevention of kidney graft
rejection subsequent to transplantation. Our partner, Lux Biosciences, is
currently conducting three separate Phase 2/Phase 3 trials investigating
ISA247 as a treatment for uveitis.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
Partnerships with Isotechnika Inc.
Isotechnika Inc. signed a collaboration agreement with Hoffman La Roche
on April 9, 2002, which licensed the worldwide rights to develop and
commercialize ISA247 for all transplant indications.
On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the use of
ISA247 and TAFA93 specifically with drug eluting devices for the non-systemic
treatment of vascular, cardiovascular, target vessel and tissue disorders.
Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an exclusive license
to develop and commercialize conjugates consisting of Cellgate's patented
transporter technology for the topical delivery of ISA247 in patients
suffering from mild to moderate psoriasis.
On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247
for the treatment and prophylaxis of all ophthalmic diseases.
This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
For further information:
For further information: Stephanie Gillis-Paulgaard, Director, Corporate
Communiations, Isotechnika Inc., Phone: (780) 487-1600, Fax: (780) 484-4105,